Skip to main content
. 2019 Jul 24;8(8):1088. doi: 10.3390/jcm8081088

Figure 6.

Figure 6

A 68-year-old patient with anaplastic astrocytoma showed a strong uptake of FMISO before the bevacizumab treatment (upper row). After the treatment, MRI showed shrinkage of the tumor, but FMISO uptake was still observed (lower row). The patient was considered a ‘MRI-only responder’.